



ADULT MEDICATION GUIDELINE

Diclofenac

Scope (Staff): All WNHS Staff

Scope (Area): Obstetrics and Gynaecology

This document should be read in conjunction with the [Disclaimer](#).

Quick Links

[Dose](#)

[Administration](#)

[Monitoring](#)

[Pregnancy and Breastfeeding](#)

Restrictions

[Formulary: Unrestricted](#)

Medication Class

Non-steroidal anti-inflammatory (NSAID)

Presentation

Forms:

Tablet (Enteric Coated): 25mg, 50mg

Suppository: 100mg

Topical gel: 1% (10mg/g)

Storage

Store at room temperature, below 25°C

Dose

Pain due to inflammation

Oral:

25 - 50mg three times a day, up to a maximum of 200mg daily

Rectal:

100mg daily, up to a maximum of 200mg daily

Local pain and inflammation in soft tissue**Topical:**

Rub gel into the affected area(s) 3 to 4 times a day

Administration**Oral**

Swallow tablets whole, do not crush or chew. Take with or soon after food

Monitoring

Renal: Avoid use if CrCl <25 mL/minute

Hepatic: Contraindicated in severe impairment

Pregnancy

1st Trimester: Consider alternative

2nd Trimester: Consider alternative

3rd Trimester: Consider alternative

For more information, please contact [KEMH Obstetric Medicines Information Service](#).

Breastfeeding

Safe to use

Comments

Regular oral NSAIDs may be commenced 12 hours after rectal diclofenac. If oral diclofenac is prescribed, the total combined oral/rectal diclofenac daily dose must not exceed 200mg.

Related Policies, Procedures & Guidelines**WNHS Clinical Practice Guidelines:**

[Perineal care and repair: Protection, Assessment, and Management \(includes episiotomy, infiltration, suturing, third/fourth degree tears\)](#)

[Labour and Post-operative Analgesia](#)

[Infections: Antibiotic Prophylaxis: Hysterosalpingogram for Infertility](#)

Breastfeeding Challenges: [Mastitis and Breast Abscess Management](#)

[Pharmacist Initiated Medications](#)

[Endorsed Midwives Prescribing](#)

[Pre-operative Medication Management](#)

WNHS Pharmaceutical and Medicines Management Guidelines:

[WNHS Medication Management Guideline “Return and Disposal of Medications”](#)









References

Australian Medicines Handbook. Diclofenac. In: Australian Medicines Handbook [Internet]. Adelaide (South Australia): Australian Medicines Handbook; 2021 [cited 2021 July 20]. Available from: <https://amhonline.amh.net.au/>

MIMS Australia. Voltaren® suppositories. In: MIMS Online [Internet]. St Leonards (New South Wales): MIMS Australia; 2021 [cited 2021 July 20]. Available from: <https://www.mimsonline.com.au>

MIMS Australia. Parecoxib (Dynastat®). In: MIMS Online [Internet]. St Leonards (New South Wales): MIMS Australia; 2021 [cited 2021 July 20]. Available from: <https://www.mimsonline.com.au>

The Royal Women’s Hospital. Diclofenac. In: Pregnancy and Breastfeeding Medicines Guide [Internet]. Parkville (Victoria): The Royal Women’s Hospital; 2021 [cited 2021 July 13]. Available from: <https://thewomenspbmg.org.au/>

Keywords	Diclofenac, suppositories, anti-inflammatory, NSAID, NSAIDs				
Document Owner:	Chief Pharmacist				
Author/ Reviewer	KEMH Pharmacy Department				
Version Info:	5.1 – Comments updated				
Date First Issued:	November 2014	Last Reviewed:	November 2018	Review Date:	20/07/2021
Endorsed by:	Medicines and Therapeutics Committee			Date:	19/08/2021
NSQHS Standards Applicable:	<input checked="" type="checkbox"/>  Std 1: Clinical Governance <input type="checkbox"/>  Std 2: Partnering with Consumers <input type="checkbox"/>  Std 3: Preventing and Controlling Healthcare Associated Infection <input checked="" type="checkbox"/>  Std 4: Medication Safety		<input type="checkbox"/>  Std 5: Comprehensive Care <input type="checkbox"/>  Std 6: Communicating for Safety <input type="checkbox"/>  Std 7: Blood Management <input type="checkbox"/>  Std 8: Recognising and Responding to Acute Deterioration		
Printed or personally saved electronic copies of this document are considered uncontrolled. Access the current version from WNHS HealthPoint.					

The health impact upon Aboriginal people has been considered, and where relevant incorporated and appropriately addressed in the development of this document (insert ISD Number). (Please refer to the Aboriginal Health Impact Statement and Declaration for Department of Health and Health Service Provider Guidelines – please delete once you have completed this).

This document can be made available in alternative formats on request for a person with a disability.

© Women and Newborn Health Service 2021

Copyright of this material is vested in the State of Western Australia unless otherwise indicated. Apart from any fair dealing for the purposes of private study, research, criticism or review, as permitted under the provisions of the Copyright Act 1968, no part may be reproduced or re-used for any purposes whatsoever without written permission of the State of Western Australia.